AA
ABEO icon

ALPS Advisors’s Abeona Therapeutics ABEO Stock Holding History

ALPS Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,632
Closed -$852K – 877
2019
Q1 		$852K Buy
4,632
+200
+5% +$35.8K 0.01% 363
2018
Q4 		$791K Buy
+4,432
New +$967K 0.01% 354

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ALPS Advisors's ABEO Position: Q2 2019 in Review

ALPS Advisors sold out of Abeona Therapeutics (ABEO) in Q2 2019, closing a stake of 4,632 shares — an estimated $852K sold.

ALPS Advisors first reported a position in ABEO in Q4 2018 and held it in 2 quarters. The position peaked at $852K in Q1 2019. 98 funds tracked by Wall St. Rank hold ABEO as of Q2 2019.

  • ALPS Advisors reported no remaining Abeona Therapeutics position as of Q2 2019 after selling out during the quarter.
  • ALPS Advisors sold 4,632 Abeona Therapeutics shares in Q2 2019, an estimated $852K.
  • ALPS Advisors first reported a position in Abeona Therapeutics in Q4 2018 and held it in 2 quarters.
  • ALPS Advisors's Abeona Therapeutics position peaked at $852K in Q1 2019.
  • 98 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2019.

Based on ALPS Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.